Prebiotics and the Management of Hyperuricemia

Last updated: June 4, 2024
Sponsor: Sun Yat-sen University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gout (Hyperuricemia)

Treatment

araboxylan

placebo control

inulin and araboxylan

Clinical Study ID

NCT06420401
Prebiotics-2024
  • Ages 18-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Hyperuricemia is a major risk factor for many chronic diesease. Recently, gut mcirobiota has been identified as a novel theraputic target for hyperuricemia. Both annimal studies and pilot human trials have demonstrated that administration of prebiotics help delay the progression of hyperuricemia throuh several mechanisms. This trial aims to examine its protective effects and potential mechanisms in clinical trials.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Local residents aged between 18-80 years old;

  • Stable weight (<5% weight change over the past 3 months);

  • Fsating uric acid > 420 umol/L for male and > 360 umol/L for female on twodifferent days;

  • Not taking uric acid lowering drugs or have stopped taking uric acid loweringdrugs for over 4 weeks at the time of recruitment;

  • Absence of any diet or medication that might interfere with uric acidmetabolims or gut microbiota, especially antibiotics, prebiotics or probioticsat the least 4 weeks before recruitment

Exclusion

Exclusion Criteria:

  • Acute illness or evidence of any acute or chronic inflammatroy of infectivediseases;

  • Participation in regular diet program more than 2 times per week in the lastest 3 months prior to recruitment;

  • Mental illness rendering them unable to understand the nature, scope, andpossible consequences of the study;

  • Women of childbearing age who are pregant, breast-feeding or preparing forpregnancy; patients who had surgey within the past 6 months or planned surgeryduring the trial period.

Study Design

Total Participants: 160
Treatment Group(s): 4
Primary Treatment: araboxylan
Phase:
Study Start date:
May 15, 2024
Estimated Completion Date:
December 31, 2026

Study Description

Hyperuricemia is a major risk factor for many chronic diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of hyperuricemia. Animal studies have demonstrated that administration of prebiotics help delay the progression of hyperuricemia through several mechanisms such as reduction in endotoxemia, and enhanced production of short-chain fatty acids and hippuric acid.

However, whether administration of prebiotics also has a protective effect in subjects with hyperuricemia remain under-explored. Moreover, whether the original gut microbiota will influence the protective effect of prebiotics remains largely unknown.

Connect with a study center

  • Department of Nutrition and Food Hygiene

    Guangzhou, Guangdong 510080
    China

    Active - Recruiting

  • Sun Yat-Sen University

    Guangzhou, Guangdong 510080
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.